product
Venglustat
Venglustat is Sanofi's investigational oral glucosylceramide synthase inhibitor, designed to reach the brain and treat the neurological effects of type 3 Gaucher disease, for which Sanofi says no treatment is approved.[1][2] Sanofi reported that it met its primary endpoints against enzyme replacement therapy in the phase 3 LEAP2MONO study.[3] The FDA is reviewing it under priority review, with a target action date of 25 November 2026.[4]
Key facts
Venglustat is an investigational oral glucosylceramide synthase inhibitor from Sanofi. It is designed to cross the blood-brain barrier and target the neurological effects of type 3 Gaucher disease.[1] Sanofi says the disease’s systemic effects are treated with enzyme replacement therapy, but no treatment is approved for its neurological symptoms.[2]
This page is not medical advice. Anyone affected should talk to their specialist.
The LEAP2MONO trial
LEAP2MONO randomized 43 patients aged 12 and older with type 3 Gaucher disease to oral venglustat or intravenous enzyme replacement therapy. Each group also received a placebo version of the other treatment, so neither patients nor doctors knew who got which (a double-dummy design).[5] On 2 February 2026 Sanofi reported that venglustat met the primary endpoints and three of four key secondary endpoints.[3] Sanofi reported that the most common adverse events with venglustat compared with enzyme replacement therapy were headache (14.3% vs 18.2%), nausea (14.3% vs 4.5%), spleen enlargement (14.3% vs 0) and diarrhoea (14.3% vs 0), and Sanofi reported no new safety signals.[6] The trial was small, and the results come from the company.[5][3]
Fabry disease
Sanofi also tested venglustat in Fabry disease. In the phase 3 PERIDOT study it did not show superiority on the patient-reported primary endpoint.[7]
Regulatory review
The FDA granted venglustat Breakthrough Therapy designation for type 3 Gaucher disease on 18 March 2026.[8] On 28 May 2026 Sanofi announced that the FDA had granted priority review to its application, with a target action date of 25 November 2026.[4] At that time Sanofi said venglustat was also under review in the EU and that no regulator had yet evaluated its safety and efficacy for this use.[9] In its third-quarter 2026 results, Sanofi listed the US decision among its expected fourth-quarter milestones and EU and Japanese decisions for 2027.[10] For background, see how FDA drug approval works.
What to watch
The next milestone is the FDA’s action, due by 25 November 2026.[4]
Read next
Health in 2026: a crash course
How drugs are tested and approved, who regulates them, and where to start on cholesterol, diabetes, dementia, ALS and cancer screening.
Questions readers ask
What is venglustat?
An investigational oral drug from Sanofi that inhibits glucosylceramide synthase and is designed to cross the blood-brain barrier, aimed at the neurological effects of type 3 Gaucher disease.[1]
Why does it matter?
Sanofi says the systemic effects of type 3 Gaucher disease are treated with enzyme replacement therapy, but no treatment is approved for its neurological symptoms.[2]
What did the phase 3 trial show?
In LEAP2MONO, 43 patients were randomized to venglustat or enzyme replacement therapy. Sanofi reported in February 2026 that venglustat met the primary endpoints and three of four key secondary endpoints.[5][3]
When will the FDA decide?
The target action date is 25 November 2026, under priority review. Sanofi also listed EU and Japanese decisions for 2027.[4][10]
Does venglustat work in Fabry disease?
In the phase 3 PERIDOT study in Fabry disease, it did not show superiority on the patient-reported primary endpoint.[7]
Sources
· 10 claims from 1 publisher
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Venglustat is Sanofi's investigational oral glucosylceramide synthase inhibitor, designed to cross the blood-brain barrier to target the neurological effects of type 3 Gaucher disease. confirmedas of 2026-02-02
- Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-02-02 (retrieved 2026-11-14)
- [2]
Sanofi says the systemic effects of type 3 Gaucher disease are treated with enzyme replacement therapy but there are no approved treatments for its neurological symptoms. confirmedas of 2026-03-18
- Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-03-18 (retrieved 2026-11-14)
- [3]
On 2 February 2026 Sanofi reported that venglustat met the primary endpoints and three of four key secondary endpoints in LEAP2MONO. confirmedas of 2026-02-02
- Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-02-02 (retrieved 2026-11-14)
- [4]
On 28 May 2026 Sanofi announced that the FDA had granted priority review to its new drug application for venglustat in type 3 Gaucher disease, with a target action date of 25 November 2026. confirmedas of 2026-05-28
- Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-05-28 (retrieved 2026-11-14)
- Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-05-28 (retrieved 2026-11-14)
- [5]
The phase 3 LEAP2MONO study randomized 43 patients aged 12 and older with type 3 Gaucher disease 1:1 to oral venglustat or intravenous enzyme replacement therapy, with matching placebos (a double-blind, double-dummy design). confirmedas of 2026-02-02
- Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-02-02 (retrieved 2026-11-14)
- [6]
In LEAP2MONO the most common adverse events with venglustat versus enzyme replacement therapy were headache (14.3% vs 18.2%), nausea (14.3% vs 4.5%), spleen enlargement (14.3% vs 0) and diarrhoea (14.3% vs 0), and Sanofi reported no new safety signals. confirmedas of 2026-05-28
- Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-05-28 (retrieved 2026-11-14)
- Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-02-02 (retrieved 2026-11-14)
- [7]
In the separate phase 3 PERIDOT study in Fabry disease, venglustat did not show superiority on the patient-reported primary endpoint. confirmedas of 2026-02-02
- Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-02-02 (retrieved 2026-11-14)
- [8]
On 18 March 2026 the FDA granted venglustat Breakthrough Therapy designation for type 3 Gaucher disease. confirmedas of 2026-03-18
- Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-03-18 (retrieved 2026-11-14)
- [9]
As of May 2026 Sanofi said venglustat was also under regulatory review for type 3 Gaucher disease in the EU, and that no regulator had yet evaluated its safety and efficacy for that use. confirmedas of 2026-05-28
- Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-05-28 (retrieved 2026-11-14)
- Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-05-28 (retrieved 2026-11-14)
- [10]
In its third-quarter 2026 results, Sanofi listed a US regulatory decision on venglustat for type 3 Gaucher disease among its expected fourth-quarter 2026 milestones, with EU and Japanese decisions listed for 2027. confirmedas of 2026-10-30
- Sanofi Q3 2026 results press release (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-10-30 (retrieved 2026-11-14)
- Sanofi Q3 2026 results press release (Form 6-K exhibit) · Sanofi (SEC filing) · Primary source · 2026-10-30 (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 25, 2026.
Cite this page
"Venglustat." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/venglustat
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.